EP4352266A2 - Krebsdetektionsverfahren, kit und system - Google Patents
Krebsdetektionsverfahren, kit und systemInfo
- Publication number
- EP4352266A2 EP4352266A2 EP22820856.7A EP22820856A EP4352266A2 EP 4352266 A2 EP4352266 A2 EP 4352266A2 EP 22820856 A EP22820856 A EP 22820856A EP 4352266 A2 EP4352266 A2 EP 4352266A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- mir
- hsa
- cancer
- mirna
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 205
- 201000011510 cancer Diseases 0.000 title claims abstract description 177
- 238000001514 detection method Methods 0.000 title claims description 28
- 239000002679 microRNA Substances 0.000 claims abstract description 277
- 108091070501 miRNA Proteins 0.000 claims abstract description 240
- 238000000034 method Methods 0.000 claims abstract description 133
- 239000000090 biomarker Substances 0.000 claims abstract description 103
- 230000014509 gene expression Effects 0.000 claims abstract description 61
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 52
- 230000035945 sensitivity Effects 0.000 claims abstract description 45
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 20
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 18
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 17
- 208000032612 Glial tumor Diseases 0.000 claims abstract description 16
- 206010018338 Glioma Diseases 0.000 claims abstract description 16
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 14
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 14
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 12
- 238000011528 liquid biopsy Methods 0.000 claims abstract description 7
- 208000011932 ovarian sarcoma Diseases 0.000 claims abstract description 7
- 239000002773 nucleotide Substances 0.000 claims description 106
- 125000003729 nucleotide group Chemical group 0.000 claims description 104
- 239000000523 sample Substances 0.000 claims description 69
- 102000040430 polynucleotide Human genes 0.000 claims description 67
- 108091033319 polynucleotide Proteins 0.000 claims description 67
- 239000002157 polynucleotide Substances 0.000 claims description 67
- 150000007523 nucleic acids Chemical class 0.000 claims description 55
- 102000039446 nucleic acids Human genes 0.000 claims description 53
- 108020004707 nucleic acids Proteins 0.000 claims description 53
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 50
- 201000005202 lung cancer Diseases 0.000 claims description 50
- 239000012472 biological sample Substances 0.000 claims description 36
- 239000012634 fragment Substances 0.000 claims description 34
- 230000000295 complement effect Effects 0.000 claims description 32
- 238000003757 reverse transcription PCR Methods 0.000 claims description 24
- 108091090409 Homo sapiens miR-5100 stem-loop Proteins 0.000 claims description 23
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 22
- 108091044796 Homo sapiens miR-1290 stem-loop Proteins 0.000 claims description 21
- 108091093160 Homo sapiens miR-1343 stem-loop Proteins 0.000 claims description 21
- 108091064270 Homo sapiens miR-4787 stem-loop Proteins 0.000 claims description 20
- 238000003860 storage Methods 0.000 claims description 19
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 18
- 210000002966 serum Anatomy 0.000 claims description 18
- 206010017758 gastric cancer Diseases 0.000 claims description 17
- 201000011549 stomach cancer Diseases 0.000 claims description 17
- 206010005003 Bladder cancer Diseases 0.000 claims description 16
- -1 hsa-miR-1273g-3p Proteins 0.000 claims description 16
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 16
- 238000004458 analytical method Methods 0.000 claims description 15
- 238000011156 evaluation Methods 0.000 claims description 15
- 201000007270 liver cancer Diseases 0.000 claims description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 230000003321 amplification Effects 0.000 claims description 13
- 238000002493 microarray Methods 0.000 claims description 13
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 13
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 12
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 12
- 201000004101 esophageal cancer Diseases 0.000 claims description 12
- 108091044953 Homo sapiens miR-1228 stem-loop Proteins 0.000 claims description 11
- 108091055552 Homo sapiens miR-1268b stem-loop Proteins 0.000 claims description 11
- 108091070489 Homo sapiens miR-17 stem-loop Proteins 0.000 claims description 11
- 108091067635 Homo sapiens miR-187 stem-loop Proteins 0.000 claims description 11
- 108091035089 Homo sapiens miR-4258 stem-loop Proteins 0.000 claims description 11
- 108091034228 Homo sapiens miR-4286 stem-loop Proteins 0.000 claims description 11
- 108091055444 Homo sapiens miR-4454 stem-loop Proteins 0.000 claims description 11
- 108091032683 Homo sapiens miR-451a stem-loop Proteins 0.000 claims description 11
- 108091063646 Homo sapiens miR-5001 stem-loop Proteins 0.000 claims description 11
- 108091038975 Homo sapiens miR-6075 stem-loop Proteins 0.000 claims description 11
- 108091044906 Homo sapiens miR-663b stem-loop Proteins 0.000 claims description 11
- 108091024552 Homo sapiens miR-6746 stem-loop Proteins 0.000 claims description 11
- 108091024622 Homo sapiens miR-6765 stem-loop Proteins 0.000 claims description 11
- 108091024424 Homo sapiens miR-6789 stem-loop Proteins 0.000 claims description 11
- 108091024287 Homo sapiens miR-6877 stem-loop Proteins 0.000 claims description 11
- 108091080212 Homo sapiens miR-8073 stem-loop Proteins 0.000 claims description 11
- 206010060862 Prostate cancer Diseases 0.000 claims description 11
- 201000009036 biliary tract cancer Diseases 0.000 claims description 11
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 11
- 238000003745 diagnosis Methods 0.000 claims description 11
- 206010009944 Colon cancer Diseases 0.000 claims description 10
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 10
- 238000003559 RNA-seq method Methods 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 238000007477 logistic regression Methods 0.000 claims description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 9
- 201000002528 pancreatic cancer Diseases 0.000 claims description 9
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 9
- 238000010208 microarray analysis Methods 0.000 claims description 8
- 238000000636 Northern blotting Methods 0.000 claims description 7
- 238000011285 therapeutic regimen Methods 0.000 claims description 7
- 210000002700 urine Anatomy 0.000 claims description 7
- 108091069019 Homo sapiens miR-124-1 stem-loop Proteins 0.000 claims description 6
- 108091069008 Homo sapiens miR-124-2 stem-loop Proteins 0.000 claims description 6
- 108091069007 Homo sapiens miR-124-3 stem-loop Proteins 0.000 claims description 6
- 108091072927 Homo sapiens miR-1260b stem-loop Proteins 0.000 claims description 6
- 108091044759 Homo sapiens miR-1268a stem-loop Proteins 0.000 claims description 6
- 108091068837 Homo sapiens miR-29b-1 stem-loop Proteins 0.000 claims description 6
- 108091068845 Homo sapiens miR-29b-2 stem-loop Proteins 0.000 claims description 6
- 108091072863 Homo sapiens miR-3131 stem-loop Proteins 0.000 claims description 6
- 108091072688 Homo sapiens miR-3192 stem-loop Proteins 0.000 claims description 6
- 108091060457 Homo sapiens miR-320b-1 stem-loop Proteins 0.000 claims description 6
- 108091062096 Homo sapiens miR-320b-2 stem-loop Proteins 0.000 claims description 6
- 108091035083 Homo sapiens miR-4257 stem-loop Proteins 0.000 claims description 6
- 108091055184 Homo sapiens miR-4513 stem-loop Proteins 0.000 claims description 6
- 108091055357 Homo sapiens miR-4525 stem-loop Proteins 0.000 claims description 6
- 108091023121 Homo sapiens miR-4706 stem-loop Proteins 0.000 claims description 6
- 108091023094 Homo sapiens miR-4708 stem-loop Proteins 0.000 claims description 6
- 108091023103 Homo sapiens miR-4710 stem-loop Proteins 0.000 claims description 6
- 108091093122 Homo sapiens miR-4727 stem-loop Proteins 0.000 claims description 6
- 108091093172 Homo sapiens miR-4736 stem-loop Proteins 0.000 claims description 6
- 108091093165 Homo sapiens miR-4740 stem-loop Proteins 0.000 claims description 6
- 108091061677 Homo sapiens miR-654 stem-loop Proteins 0.000 claims description 6
- 108091061569 Homo sapiens miR-663a stem-loop Proteins 0.000 claims description 6
- 108091060464 Homo sapiens miR-668 stem-loop Proteins 0.000 claims description 6
- 108091024427 Homo sapiens miR-6787 stem-loop Proteins 0.000 claims description 6
- 108091024601 Homo sapiens miR-6802 stem-loop Proteins 0.000 claims description 6
- 108091024415 Homo sapiens miR-6840 stem-loop Proteins 0.000 claims description 6
- 108091083050 Homo sapiens miR-7977 stem-loop Proteins 0.000 claims description 6
- 108091080286 Homo sapiens miR-8060 stem-loop Proteins 0.000 claims description 6
- 108091070380 Homo sapiens miR-92a-1 stem-loop Proteins 0.000 claims description 6
- 108091070381 Homo sapiens miR-92a-2 stem-loop Proteins 0.000 claims description 6
- 108091063740 Homo sapiens miR-92b stem-loop Proteins 0.000 claims description 6
- 108091007702 MIR1260B Proteins 0.000 claims description 6
- 238000007901 in situ hybridization Methods 0.000 claims description 6
- 210000003296 saliva Anatomy 0.000 claims description 6
- 108091044938 Homo sapiens miR-1238 stem-loop Proteins 0.000 claims description 4
- 238000007637 random forest analysis Methods 0.000 claims description 4
- 238000012706 support-vector machine Methods 0.000 claims description 4
- 108091068855 Homo sapiens miR-103a-1 stem-loop Proteins 0.000 claims description 3
- 108091068838 Homo sapiens miR-103a-2 stem-loop Proteins 0.000 claims description 3
- 108091068928 Homo sapiens miR-107 stem-loop Proteins 0.000 claims description 3
- 108091038941 Homo sapiens miR-1199 stem-loop Proteins 0.000 claims description 3
- 108091044921 Homo sapiens miR-1225 stem-loop Proteins 0.000 claims description 3
- 108091044881 Homo sapiens miR-1246 stem-loop Proteins 0.000 claims description 3
- 108091064840 Homo sapiens miR-1469 stem-loop Proteins 0.000 claims description 3
- 108091068998 Homo sapiens miR-191 stem-loop Proteins 0.000 claims description 3
- 108091070494 Homo sapiens miR-22 stem-loop Proteins 0.000 claims description 3
- 108091070492 Homo sapiens miR-23a stem-loop Proteins 0.000 claims description 3
- 108091069063 Homo sapiens miR-23b stem-loop Proteins 0.000 claims description 3
- 108091065453 Homo sapiens miR-296 stem-loop Proteins 0.000 claims description 3
- 108091072912 Homo sapiens miR-3122 stem-loop Proteins 0.000 claims description 3
- 108091072687 Homo sapiens miR-3191 stem-loop Proteins 0.000 claims description 3
- 108091072679 Homo sapiens miR-3194 stem-loop Proteins 0.000 claims description 3
- 108091072689 Homo sapiens miR-320e stem-loop Proteins 0.000 claims description 3
- 108091067008 Homo sapiens miR-342 stem-loop Proteins 0.000 claims description 3
- 108091056656 Homo sapiens miR-3648-1 stem-loop Proteins 0.000 claims description 3
- 108091045458 Homo sapiens miR-3648-2 stem-loop Proteins 0.000 claims description 3
- 108091056607 Homo sapiens miR-3688-1 stem-loop Proteins 0.000 claims description 3
- 108091064272 Homo sapiens miR-3688-2 stem-loop Proteins 0.000 claims description 3
- 108091067269 Homo sapiens miR-371a stem-loop Proteins 0.000 claims description 3
- 108091035094 Homo sapiens miR-4259 stem-loop Proteins 0.000 claims description 3
- 108091055647 Homo sapiens miR-4429 stem-loop Proteins 0.000 claims description 3
- 108091055376 Homo sapiens miR-4448 stem-loop Proteins 0.000 claims description 3
- 108091055440 Homo sapiens miR-4455 stem-loop Proteins 0.000 claims description 3
- 108091055366 Homo sapiens miR-4480 stem-loop Proteins 0.000 claims description 3
- 108091055335 Homo sapiens miR-4515 stem-loop Proteins 0.000 claims description 3
- 108091055348 Homo sapiens miR-4529 stem-loop Proteins 0.000 claims description 3
- 108091054145 Homo sapiens miR-4534 stem-loop Proteins 0.000 claims description 3
- 108091023271 Homo sapiens miR-4635 stem-loop Proteins 0.000 claims description 3
- 108091023054 Homo sapiens miR-4652 stem-loop Proteins 0.000 claims description 3
- 108091023056 Homo sapiens miR-4658 stem-loop Proteins 0.000 claims description 3
- 108091023081 Homo sapiens miR-4687 stem-loop Proteins 0.000 claims description 3
- 108091093209 Homo sapiens miR-4718 stem-loop Proteins 0.000 claims description 3
- 108091093144 Homo sapiens miR-4754 stem-loop Proteins 0.000 claims description 3
- 108091093145 Homo sapiens miR-4755 stem-loop Proteins 0.000 claims description 3
- 108091064330 Homo sapiens miR-4771-1 stem-loop Proteins 0.000 claims description 3
- 108091064323 Homo sapiens miR-4771-2 stem-loop Proteins 0.000 claims description 3
- 108091064333 Homo sapiens miR-4776-1 stem-loop Proteins 0.000 claims description 3
- 108091064335 Homo sapiens miR-4776-2 stem-loop Proteins 0.000 claims description 3
- 108091058617 Homo sapiens miR-6131 stem-loop Proteins 0.000 claims description 3
- 108091061646 Homo sapiens miR-619 stem-loop Proteins 0.000 claims description 3
- 108091061609 Homo sapiens miR-648 stem-loop Proteins 0.000 claims description 3
- 108091061608 Homo sapiens miR-650 stem-loop Proteins 0.000 claims description 3
- 108091024578 Homo sapiens miR-6717 stem-loop Proteins 0.000 claims description 3
- 108091024386 Homo sapiens miR-6861 stem-loop Proteins 0.000 claims description 3
- 108091024289 Homo sapiens miR-6875 stem-loop Proteins 0.000 claims description 3
- 108091083060 Homo sapiens miR-7975 stem-loop Proteins 0.000 claims description 3
- 108091087068 Homo sapiens miR-920 stem-loop Proteins 0.000 claims description 3
- 108091007774 MIR107 Proteins 0.000 claims description 2
- 108091061603 Homo sapiens miR-651 stem-loop Proteins 0.000 claims 4
- 108091007707 MIR4454 Proteins 0.000 claims 3
- 108091070493 Homo sapiens miR-21 stem-loop Proteins 0.000 claims 2
- 108091060471 Homo sapiens miR-320c-1 stem-loop Proteins 0.000 claims 2
- 108091078079 Homo sapiens miR-320c-2 stem-loop Proteins 0.000 claims 2
- 108091008065 MIR21 Proteins 0.000 claims 2
- 210000004185 liver Anatomy 0.000 abstract description 11
- 210000004072 lung Anatomy 0.000 abstract description 11
- 210000003445 biliary tract Anatomy 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 description 24
- 238000012360 testing method Methods 0.000 description 22
- 238000010200 validation analysis Methods 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 17
- 239000002299 complementary DNA Substances 0.000 description 14
- 238000009396 hybridization Methods 0.000 description 14
- 238000010606 normalization Methods 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 238000011161 development Methods 0.000 description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 230000002611 ovarian Effects 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 206010039491 Sarcoma Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000002591 computed tomography Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 4
- 239000000039 congener Substances 0.000 description 4
- 238000002790 cross-validation Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 108091027963 non-coding RNA Proteins 0.000 description 4
- 102000042567 non-coding RNA Human genes 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 238000002869 basic local alignment search tool Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 238000013211 curve analysis Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 2
- 108091024577 Homo sapiens miR-6511b-1 stem-loop Proteins 0.000 description 2
- 108091059382 Homo sapiens miR-6511b-2 stem-loop Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091030146 MiRBase Proteins 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000012165 high-throughput sequencing Methods 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 108091007428 primary miRNA Proteins 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000013179 statistical model Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- IVDRCZNHVGQBHZ-UHFFFAOYSA-N 2-butoxyethyl 2-(3,5,6-trichloropyridin-2-yl)oxyacetate Chemical compound CCCCOCCOC(=O)COC1=NC(Cl)=C(Cl)C=C1Cl IVDRCZNHVGQBHZ-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108091067471 Homo sapiens miR-211 stem-loop Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 238000001347 McNemar's test Methods 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 241000702619 Porcine parvovirus Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108020005093 RNA Precursors Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 1
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001369 bisulfite sequencing Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 108091092240 circulating cell-free DNA Proteins 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000009607 mammography Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000005055 memory storage Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 108091047577 miR-149 stem-loop Proteins 0.000 description 1
- 108091087639 miR-2861 stem-loop Proteins 0.000 description 1
- 108091069243 miR-4463 stem-loop Proteins 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000004803 parallel plate viscometry Methods 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 229920000553 poly(phenylenevinylene) Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000007859 posttranscriptional regulation of gene expression Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Definitions
- the present invention relates generally to the technical field of disease screening, detection and diagnosis, and more specifically relates to a method, a kit, a system, and a non- transitory storage medium for the detection of one or multiple human cancers.
- miRNAs are small single-stranded non-coding RNA molecules of an average of 22 nucleotides long encoded by their corresponding genes in the human genome.
- the miRNAs function in negative post-transcriptional regulation of gene expression primarily by binding with complementary sequences in the 3’ untranslated region (3’ UTR) of mRNA molecules.
- miRNAs appear to regulate more than 50% human genes, and abnormal expression of miRNAs has been implicated in many human cancers. miRNAs are also abundant as extracellular circulating molecules released into circulation by tumor cells either through cell death or by exosome- mediated signaling. Combined with its remarkable stability in the blood and other body fluids, circulating cell-free miRNAs have the potential to serve as noninvasive biomarkers for cancer screening and diagnosis.
- the present disclosure provides a multi-cancer detection approach (i.e. method, kit, and system) by means of an miRNA biomarker set consisting of at least one miRNA biomarker.
- the approach is substantially based on the expression profile of the miRNA biomarker set, which can be determined from a biological sample obtained from a human subject.
- a biological sample can notably be a liquid biopsy sample including a blood sample, a serum sample, a plasma sample, a urine sample, a saliva sample, or a spatum sample to thereby allow a non-invasive or minimum- invasive detection for the cancer.
- the approach can be employed to accurately and reliably detect whether a human subject has one of the cancers including lung cancer, biliary tract cancer, bladder cancer, colorectal cancer, esophageal cancer, gastric cancer, glioma cancer, liver cancer, pancreatic cancer, prostate cancer, ovarian cancer, and sarcoma.
- a method for detecting a cancer from a biological sample obtained from a subject substantially includes the following three steps (l)-(3): [0008] Step (1): determining an expression profile of an miRNA biomarker set consisting of at least one miRNA from the biological sample.
- the miRNA biomarker set comprises hsa- miR-5100.
- Step (2) calculating a diagnostic index of the biological sample based on the expression profile of the miRNA biomarker set.
- Step (3) classifying the subject as having the cancer or not based on the value of the calculated diagnostic index. If the calculated diagnostic index is greater than or equal to a pre determined threshold, the subject is classified as having the cancer; or if otherwise the subject is classified as not having the cancer.
- the method is capable of achieving diagnostic accuracy having an AUC value greater than approximately 0.780.
- the expression profile of an miRNA biomarker set is substantially a dataset containing expression level data that has been determined for each and every miRNA member contained in the miRNA biomarker set.
- pre-determined threshold is referred to as a cut-point value of the diagnostic index that can be used to determine with a given specificity/sensitivity if a subject has the cancer type or not. It is typically pre-determined based on an existing dataset comprising a range of diagnostic index values that have been obtained and calculated for an existing population of subjects known to have, and/or known to be absent of, the disease. For example, in the EXAMPLE 1 provided below, when the miRNA biomarker set consists of any one of the top 100 miRNAs (corresponding to SEQ ID NOS: 1-100), the AUC can reach a level that is greater than 0.780 (i.e.
- the miRNA biomarker set further comprises, in addition to hsa-miR-5100 (corresponding to SEQ ID NO: 1), one or more of the other 99 miRNAs listed in Table 1, i.e.
- hsa-miR-1343-3p hsa-miR-1290, hsa-miR-4787-3p, hsa- miR-6877-5p, hsa-miR-17-3p, hsa-miR-6765-5p, hsa-miR- 1268b, hsa-miR-4258, hsa-miR-451a, hsa-miR-1228-5p, hsa-miR-8073, hsa-miR-4454, hsa-miR-187-5p, hsa-miR-4286, hsa-miR- 6746-5p, hsa-miR-663b, hsa-miR-6075, hsa-miR-5001-5p, hsa-miR-6789-5p, hsa-miR-4513, hs
- the miRNA biomarker set further comprises, in addition to hsa-miR-5100, one or more of the other top 50 miRNAs listed in Table 1, i.e. hsa-miR-1343-3p, hsa-miR-1290, hsa-miR-4787-3p, hsa-miR-6877-5p, hsa-miR-17-3p, hsa-miR-6765-5p, hsa-miR- 1268b, hsa-miR-4258, hsa-miR-451a, hsa-miR-1228-5p, hsa-miR- 8073, hsa-miR-4454, hsa-miR- 187-5p, hsa-miR-4286, hsa-miR-6746-5p, hsa-m
- the miRNA biomarker set further comprises, in addition to hsa-miR-5100, one or more of the other top 20 miRNAs listed in Table 1, i.e. hsa-miR-1343-3p, hsa-miR-1290, hsa-miR-4787-3p, hsa-miR-6877-5p, hsa-miR- 17-3 p, hsa-miR-6765-5p, hsa-miR- 1268b, hsa-miR-4258, hsa-miR-451a, hsa-miR- 1228-5p, hsa-miR- 8073, hsa-miR-4454, hsa-miR- 187-5p, hsa-miR-4286, hsa-miR-6746-5p, hs
- the miRNA biomarker set further comprises, in addition to hsa-miR-5100, one or more of the other top 4 miRNAs listed in Table 1, i.e. hsa-miR-1343-3p, hsa-miR-1290, and hsa-miR-4787-3p, which are ranked based on the adjusted P value and correspond to SEQ ID NOS: 2-4 respectively.
- the miRNA biomarker set consists of the top 4 miRNAs listed in Table 1, i.e.
- hsa-miR-5100 hsa-miR- 1343-3p, hsa-miR-1290, and hsa-miR-4787-3p, which correspond to SEQ ID NOS: 1-4 respectively.
- the method can optionally be further configured to be capable of achieving diagnostic accuracy having a higher AUC value.
- the method is configured to be capable of achieving diagnostic accuracy having an AUC value greater than approximately 0.850.
- the cancer that can be detected can be selected from a group consisting of lung cancer, biliary tract cancer, bladder cancer, colorectal cancer, esophageal cancer, gastric cancer, glioma cancer, liver cancer, pancreatic cancer, prostate cancer, ovarian cancer, and sarcoma.
- the method is configured to be capable of achieving diagnostic accuracy having an AUC value greater than approximately 0.950.
- the cancer that can be detected can be selected from a group consisting of lung cancer, biliary tract cancer, bladder cancer, colorectal cancer, esophageal cancer, gastric cancer, glioma cancer, liver cancer, ovarian cancer, pancreatic cancer, and prostate cancer.
- the method is configured to be capable of achieving diagnostic accuracy having an AUC value greater than approximately 0.990.
- the cancer that can be detected can be selected from a group consisting of lung cancer, biliary tract cancer, bladder cancer, esophageal cancer, gastric cancer, glioma cancer, and prostate cancer.
- the method is configured to be capable of achieving a diagnostic accuracy having an AUC value greater than approximately 0.999.
- the cancer that can be detected can be lung cancer or gastric cancer.
- the method can optionally be configured to be capable of achieving diagnostic accuracy having different sensitivity and specificity levels.
- the method is configured to be capable of achieving diagnostic accuracy having a sensitivity greater than approximately 68.0% while having a specificity greater than approximately 99.0%.
- the cancer that can be detected can be selected from a group consisting of lung cancer, biliary tract cancer, bladder cancer, colorectal cancer, esophageal cancer, gastric cancer, glioma cancer, liver cancer, pancreatic cancer, prostate cancer, ovarian cancer, and sarcoma.
- the method is configured to be capable of achieving diagnostic accuracy having a sensitivity greater than approximately 83.0% while having a specificity greater than approximately 99.0%.
- the cancer that can be detected can be selected from a group consisting of lung cancer, biliary tract cancer, bladder cancer, colorectal cancer, esophageal cancer, gastric cancer, glioma cancer, liver cancer, pancreatic cancer, and prostate cancer.
- the method is configured to be capable of achieving diagnostic accuracy having a sensitivity greater than approximately 99.0% and having a specificity greater than approximately 99.0%.
- the cancer that can be detected can be lung cancer or gastric cancer.
- step (2) of calculating the diagnostic index of the biological sample based on the expression profile of the miRNA biomarker set the diagnostic index is calculated via an unweighted model.
- the diagnostic index is calculated via a weighted model using weights from one selected from a group consisting of Linear Models for Microarray Data (limma) model, logistic regression model, linear discriminant analysis (LDA) model, conditional logistic regression model, lasso regression model, ridge regression model, random forest, support vector machine, and probit regression model. Further optionally, the diagnostic index is calculated via a weighted model using weights from the limma model.
- limma Linear Models for Microarray Data
- LDA linear discriminant analysis
- the terms “unweighted model” and “weighted model” are to be understood within the common definition as well appreciated by people skilled in the art.
- “unweighted model” it refers to a situation where no weight is applied for each miRNAin the miRNA biomarker set when calculating the diagnostic index.
- weighted model it refers to as a situation where a corresponding weight is applied for each miRNA in the miRNA biomarker set when calculating the diagnostic index.
- the phrase “the diagnostic index is calculated via a weighted model” can be understood such that for any miRNA/ in the miRNA biomarker set, not all /, are equal (i.e. there are at least two miRNAs which have different weights).
- Linear Models for Microarray Data (limma) model (Ritchie et al. 2015), “logistic regression model” (Venable and Ripley 2002), “linear discriminant analysis (LDA) model” (Venable and Ripley 2002), “conditional logistic regression model” (Venable and Ripley 2002), “lasso regression model” (Tibshirani 1996), “ridge regression model” (Hoerl and Kennard 1970), “random forest” (Ripley 1996), “support vector machine” (Ripley 1996), and “probit regression model” (Venable and Ripley 2002) is substantially a probability-modeling statistical model that models abides by the definition commonly appreciated by people skilled in the field, the details of which can be referenced by the reference included immediately behind.
- step (3) comprises: classifying the subject as having the cancer if the normalized diagnostic index is equal to or greater than a preset cut-point; or classifying the subject as not having the cancer if otherwise.
- the normalized diagnostic index is calculated based on formula (II):
- the parami OCation and param SCaie are respectively a location parameter and a scale parameter configured to allow the normalized diagnostic index to be within a range no less than a first preset value and no greater than a second preset value.
- the parami OCation is substantially a location parameter configured to shift the minimum of the normalized diagnostic index to the first preset value
- param SCaie is substantially a scale parameter configured to scale the maximum of the normalized diagnostic index to the second value.
- first preset value and the second preset value are respectively the minimum and maximum in the range of normalized diagnostic index values that have been obtained and calculated from an existing population of subjects known to have and known not to have the cancer, with outliers excluded.
- multiple settings can be applied.
- the diagnostic index values are determined to have a range of 600 to 1600 excluding outliers (see)
- the parami OCation and param SCaie can be respectively set to 600 and 100 so that the final normalized diagnostic index can be no less than 0 and no greater than 10. It is note that this normalization scheme was employed in the below EXAMPLE 1.
- the parami OCation and param SCaie can be respectively set to 600 and 1000, so that the final normalized diagnostic index can be set to be no less than 0 and no greater than 1. Further alternatively, the parami OCation and param SCaie can be respectively set to 600 and 10, so that the final normalized diagnostic index can be set to be no less than 0 and no greater than 100. Further alternatively, the parami OCation and param SCaie can be respectively set to 350 and 250, so that the final normalized diagnostic index can be set to be no less than 1 and no greater than 5.
- the pre-set cut-point can optionally be set as 5.1 to thereby allow the method to have a specificity that is greater than approximately 0.95, or optionally can be set as 6.0 to thereby allow the method to have a specificity that is greater than approximately 0.99.
- the biological sample is a liquid biopsy sample selected from a group consisting of a blood sample, a serum sample, a plasma sample, a urine sample (Yun et al. 2012), a saliva sample (Park et al. 2009), and a spatum sample.
- the expression profile of the miRNA biomarker set in step (1) of determining an expression profile of an miRNA biomarker set consisting of at least one miRNA from the biological sample, can optionally be obtained by means of Northern Blotting, microarray analysis, RNA-sequencing, or RNA in-situ hybridization, or can optionally be obtained by means of a nucleic acid amplification procedure, comprising reverse-transcription PCR (RT-PCR), quantitative RT-PCR (qRT-PCR), or digital RT- PCR.
- RT-PCR reverse-transcription PCR
- qRT-PCR quantitative RT-PCR
- digital RT- PCR digital RT-PCR
- each of the above miRNA detection approaches is to be understood within the common definition well-appreciated by people of ordinary skills in the field. More details for implementing these approaches to determine the expression profile of the miRNA biomarker set will be provided below.
- the method optionally further comprises a step of performing an evaluation of the subject, wherein said evaluation comprises a diagnosis of the cancer or a detection of a recurrence of the cancer.
- the phrase “diagnosis of the cancer” is referred to as the detection of the cancer in a subject previously known not to have the cancer, whereas the phrase “recurrence of the cancer” is referred to as the detection of the cancer again in a subject with the cancer who has previously been treated to remove the cancer to become cancer-free.
- the method optionally further comprises a step of administering to the subject a therapeutic regimen when the subject is classified as having the cancer.
- a therapeutic regimen when the subject is classified as having the cancer.
- a variety of known therapeutic regimens can be administered in the method, which include surgery, radiotherapy, chemotherapy, hormonal therapy, targeted therapy, immunotherapy or the combination thereof. These above therapeutic regimens have been well- established for each different cancer mentioned above.
- the method optionally further comprises a step of performing a diagnostic procedure on the subject when the subject is classified as having the cancer.
- the diagnostic procedure may optionally comprise physical examination, pathological examination of a biopsy from the subject, immunohistochemistry examination, or imaging examination such as x-rays, computed tomography (CT), ultrasonography, and/or magnetic resonance imaging.
- the present disclosure further provides a kit for detecting a cancer from a biological sample obtained from a subject, which is substantially employed for implementing the method described in the first aspect.
- kits are referred to as a collection of articles and/or instructions.
- An article included in the kit can be a physical entity or a component thereof.
- articles that can be included in the kit as disclosed herein can include one or more nucleic acids (e.g. polynucleotides), or one or more device, apparatus or equipment (e.g. a molecular array or microarray that comprises the one or more nucleic acids).
- An instruction included in the kit can be a description of the specific steps to be performed (e.g. a manual), which can be printed on a physical medium (e.g. paper, card, etc.), on a computer- readable storage medium (e.g. hard disc, compact disc or CD, flash drive, etc.), or even stored in the internet (e.g. in an accessible cloud space), etc.
- the kit can comprise at least the following components (1) and (2) (i.e. articles and/or instructions):
- Component (1) at least one nucleic acid, each capable of specifically recognizing each miRNA in an miRNA biomarker set to thereby allow an expression profile of the miRNA biomarker set to be obtained from the biological sample.
- the miRNA biomarker set comprises hsa-miR-5100 (SEQ ID NO: 1).
- Component (2) at least one instruction, comprising a first instruction and a second instruction.
- the second instruction is configured for classifying the subject as having the cancer or not, wherein the subject is classified as having the cancer if the calculated diagnostic index is greater than or equal to a pre-determined threshold or as not having the cancer if otherwise.
- the at least one nucleic acid can optionally comprise a polynucleotide capable of specifically hybridizing under a stringent condition to: either (a) a polynucleotide comprising or consisting of a nucleotide sequence of SEQ ID NO: 1, a derivative thereof, a variant thereof having at least 80% sequence identity, or a fragment thereof comprising 15 or more consecutive nucleotides; or (b) a polynucleotide comprising or consisting of a nucleotide sequence complementary to a nucleotide sequence of SEQ ID NO: 1, a derivative thereof, a variant thereof having at least 80% sequence identity, or a fragment thereof comprising 15 or more consecutive nucleotides.
- the miRNA biomarker set further comprises, in addition to hsa-miR-5100, one or more of the other 99 miRNAs listed in Table 1.
- the at least one nucleic acid can optionally further comprise at least one polynucleotide, each capable of specifically hybridizing under a stringent condition to: either (a) a polynucleotide comprising or consisting of a nucleotide sequence of any one of SEQ ID NOS: 2-100, a derivative thereof, a variant thereof having at least 80% sequence identity, or a fragment thereof comprising 15 or more consecutive nucleotides; or (b) a polynucleotide comprising or consisting of a nucleotide sequence complementary to a nucleotide sequence of any one of SEQ ID NOS: 2-100, a derivative thereof, a variant thereof having at least 80% sequence identity, or a fragment thereof comprising 15 or more consecutive nucle
- the miRNA biomarker set further comprises, in addition to hsa-miR-5100, one or more of the other top 50 miRNAs listed in Table 1.
- the at least one nucleic acid can optionally further comprise at least one polynucleotide, each capable of specifically hybridizing under a stringent condition to: either (a) a polynucleotide comprising or consisting of a nucleotide sequence of any one of SEQ ID NOS: 2-50, a derivative thereof, a variant thereof having at least 80% sequence identity, or a fragment thereof comprising 15 or more consecutive nucleotides; or (b) a polynucleotide comprising or consisting of a nucleotide sequence complementary to a nucleotide sequence of any one of SEQ ID NOS: 2-50, a derivative thereof, a variant thereof having at least 80% sequence identity, or a fragment thereof comprising 15 or more consecutive nucleotides; or (b) a polynucleotide comprising or consist
- the miRNA biomarker set further comprises, in addition to hsa-miR-5100, one or more of the other top 20 miRNAs listed in Table 1.
- the at least one nucleic acid can optionally further comprise at least one polynucleotide, each capable of specifically hybridizing under a stringent condition to: either (a) a polynucleotide comprising or consisting of a nucleotide sequence of any one of SEQ ID NOS: 2-20, a derivative thereof, a variant thereof having at least 80% sequence identity, or a fragment thereof comprising 15 or more consecutive nucleotides; or (b) a polynucleotide comprising or consisting of a nucleotide sequence complementary to a nucleotide sequence of any one of SEQ ID NOS: 2-20, a derivative thereof, a variant thereof having at least 80% sequence identity, or a fragment thereof comprising 15 or more consecutive nucleotides; or (b) a polynucleotide comprising or consist
- the miRNA biomarker set consists of the top 20 miRNAs in Table 1, and correspondingly, in component (1) of the kit, the at least one nucleic acid consists of a total of 20 polynucleotides which are respectively capable of specifically hybridizing under a stringent condition to: either (a) polynucleotides respectively comprising or consisting of nucleotide sequences of SEQ ID NOS: 1-20, derivatives thereof, variants thereof each having at least 80% sequence identity, or fragments thereof each comprising 15 or more consecutive nucleotides; or (b) polynucleotides respectively comprising or consisting of nucleotide sequences which are respectively complementary to nucleotide sequences of SEQ ID NOS: 1-20, derivatives thereof, variants thereof each having at least 80% sequence identity, or fragments thereof each comprising 15 or more consecutive nucleotides.
- the miRNA biomarker set further comprises, in addition to hsa-miR-5100, one or more of the other top 4 miRNAs listed in Table 1.
- the at least one nucleic acid can optionally further comprise at least one polynucleotide, each capable of specifically hybridizing under a stringent condition to: either (a) a polynucleotide comprising or consisting of a nucleotide sequence of any one of SEQ ID NOS: 2-4, a derivative thereof, a variant thereof having at least 80% sequence identity, or a fragment thereof comprising 15 or more consecutive nucleotides; or (b) a polynucleotide comprising or consisting of a nucleotide sequence complementary to a nucleotide sequence of any one of SEQ ID NOS: 2-4, a derivative thereof, a variant thereof having at least 80% sequence identity, or a fragment thereof comprising 15 or more consecutive nucleotides; or (b) a polynucleotide comprising or consist
- the miRNA biomarker set consists of the top 4 miRNAs in Table 1, i.e. hsa-miR-5100, hsa-miR-1343-3p, hsa-miR-1290, and hsa-miR-4787-3p, and correspondingly, in component (1) of the kit, the at least one nucleic acid consists of a total of 4 polynucleotides which are respectively capable of specifically hybridizing under a stringent condition to: either (a) polynucleotides respectively comprising or consisting of nucleotide sequences of SEQ ID NOS: 1-4, derivatives thereof, variants thereof each having at least 80% sequence identity, or fragments thereof each comprising 15 or more consecutive nucleotides; or (b) polynucleotides respectively comprising or consisting of nucleotide sequences which are respectively complementary to nucleotide sequences of SEQ ID NOS: 1-4, derivatives thereof, variant
- the diagnostic index in the first sub-instruction of the first instruction in component (2), can be calculated via an unweighted model, or alternatively via a weighted model using weights from one of the probability-modeling statistical models that have been provided above in the first aspect.
- the diagnostic index is calculated via a weighted model using weights from the limma model.
- the pre-determined threshold can be set as 1110, and the second instruction further indicates that the classification using 1110 as the pre determined threshold has a specificity > 0.95.
- the pre-determined threshold can be set as 1200, and the second instruction further indicates that such classification using 1200 as the pre-determined threshold has a specificity > 0.99.
- the first instruction further comprises a second sub-instruction for obtaining a normalized diagnostic index based on the diagnostic index calculated according to the first sub-instruction, and in the second instruction, the subject is classified as having the cancer if the normalized diagnostic index is greater than or equal to a preset cut-point or as not having the cancer if otherwise.
- the normalization process is substantially identical to the normalization process mentioned above in the first method aspect above, whose description will be skipped in here.
- the normalized diagnostic index is calculated via a weighted model using weights from the limma model, and the first preset value is 0, and the second preset value is 10.
- the preset cut-point can be set optionally as 5.1 or 6.0, to thereby allow the classification using the preset cut-point to have a specificity that is > 0.95 or > 0.99, respectively.
- the at least one instruction in component (2) in the kit may further comprise a third instruction for performing an evaluation of the subj ect, wherein said evaluation comprises a diagnosis of the cancer or a detection of a recurrence of the cancer; or may further comprise a fourth instruction for administering to the subject a therapeutic regimen when the subject is classified as having the cancer.
- the at least one instruction in component (2) in the kit may further comprise a first additional instruction for obtaining the expression profile of the miRNA biomarker set, comprising a procedure for performing Northern Blotting, microarray analysis, RNA-sequencing, or RNAin-situ hybridization by means of the at least one nucleic acid.
- the at least one nucleic acid may optionally be arranged on a molecular array.
- the kit may further comprise at least one set of amplification primers, each set capable of specifically amplifying each of the at least one miRNA in the miRNA biomarker set from the biological sample.
- the at least one instruction in component (2) in the kit may further comprise a second additional instruction for obtaining the expression profile of the miRNA biomarker set, comprising a procedure for performing reverse- transcription PCR (RT-PCR), quantitative RT-PCR (qRT-PCR), or digital RT-PCR by means of the at least one nucleic acid and the at least one set of amplification primers.
- RT-PCR reverse- transcription PCR
- qRT-PCR quantitative RT-PCR
- digital RT-PCR digital RT-PCR by means of the at least one nucleic acid and the at least one set of amplification primers.
- the biological sample can be a liquid biopsy sample selected from a group consisting of a blood sample, a serum sample, a plasma sample, a urine sample, a saliva sample, and a spatum sample.
- the present disclosure further provides a system for detecting a cancer in a subject.
- the system is substantially a computerized system comprising a collection of hardware (e.g. processor, memory, I/O interface, storage medium, etc.) and software (i.e. computer programs, including operation system software, and specific program software, etc.), which are configured to collaboratively work so as to collectively implement all or some steps of the method as described above in the first aspect.
- the system comprises a processor and a non-transitory storage medium.
- the non-transitory storage medium is configured to contain a software (i.e. program instructions) for execution by the processor, and the program instructions are configured to cause the processor to execute the various steps of the method according to the various different embodiments of the method that are described above in the first aspect.
- the present disclosure further provides a non-transitory storage medium, configured to store computer-executable program instructions which, when executed by a processor, cause the processor to execute the method according to the various different embodiments of the method that are described above in the first aspect.
- a “subject” means a mammal such as a primate including a human and a chimpanzee, a pet animal including a dog and a cat, a livestock animal including cattle, a horse, sheep, and a goat, and a rodent including a mouse and a rat.
- the term “healthy subject” also means such a mammal without the cancer to be detected. It is to be noted that the whole disclosure concerns more specifically human subjects, but can optionally be applied to other non-human mammals as well.
- nucleic acid As used herein, the term “polynucleotide” is interchangeable with “nucleic acid”, and is referred to as a nucleic acid including all of RNA, DNA, and RNA/DNA (chimera).
- the DNA includes all of cDNA, genomic DNA, and synthetic DNA.
- the RNA includes all of total RNA, mRNA, rRNA, miRNA, siRNA, snoRNA, snRNA, non-coding RNA and synthetic RNA.
- fragment is a polynucleotide having a nucleotide sequence having a consecutive portion of a polynucleotide and desirably has a length of 15 or more nucleotides, e.g. 15, 16, 17, 18, 19, etc. nucleotides.
- gene is intended to include not only RNA and double- stranded DNA but also each single-stranded DNA such as a plus strand (or a sense strand) or a complementary strand (or an antisense strand) constituting the duplex. The gene is not particularly limited by its length.
- the “gene” includes all of double-stranded DNA including human genomic DNA, single-stranded DNA (plus strand) including cDNA, single-stranded DNA having a sequence complementary to the plus strand (complementary strand), miRNA (miRNA), and their fragments, and their transcripts, unless otherwise specified.
- the “gene” includes not only a “gene” represented by a particular nucleotide sequence (or SEQ ID NO) but “nucleic acids” encoding RNAs having biological functions equivalent to an RNA encoded by the gene, for example, a congener (i.e., a homolog or an ortholog), a variant (e.g., a genetic polymorph), and a derivative.
- nucleic acid encoding a congener, a variant, or a derivative
- a “nucleic acid” having a nucleotide sequence hybridizing under stringent conditions described later to a complementary sequence of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 100 or a nucleotide sequence derived from the nucleotide sequence by the replacement of the nucleotide "U” (or “u") with the nucleotide "T” (or “t”).
- the “gene” is not particularly limited by its functional region and can contain, for example, an expression control region, a coding region, an exon, or an intron.
- the “gene” may be contained in a cell or may exist alone after being released into the outside of a cell. Alternatively, the “gene” may be in a state enclosed in a vesicle called exosome.
- microRNA is intended to mean a 15- to 25-nucleotide non-coding RNA that is transcribed as an RNA precursor having a hairpin-like structure, cleaved by a dsRNA-cleaving enzyme which has RNase III cleavage activity, integrated into a protein complex called RISC, and involved in the suppression of translation of mRNA, unless otherwise specified.
- miRNA as used herein includes not only a “miRNA” represented by a particular nucleotide sequence (or SEQ ID NO) but a precursor of the “miRNA” (pre-miRNA or pri-miRNA), and miRNAs having biological functions equivalent thereto, for example, a congener (i.e., a homolog or an ortholog), a variant (e.g., a genetic polymorph), and a derivative.
- a congener i.e., a homolog or an ortholog
- a variant e.g., a genetic polymorph
- Such a precursor, a congener, a variant, or a derivative can be specifically identified using miRBase Release 20 (Kozomara and Griflfiths-Jones, 2010), and examples thereof can include an “miRNA” having a nucleotide sequence hybridizing under stringent conditions described later to a complementary sequence of any particular nucleotide sequence represented by any of SEQ ID NOS: 1 to 100.
- miRNA as used herein may be a gene product of a miRNA gene.
- Such a gene product includes a mature miRNA (e.g., a 15- to 25-nucleotide or 19- to 25-nucleotide non-coding RNA involved in the suppression of translation of mRNA as described above) or a miRNA precursor (e.g., pre-miRNA or pri-miRNA).
- a mature miRNA e.g., a 15- to 25-nucleotide or 19- to 25-nucleotide non-coding RNA involved in the suppression of translation of mRNA as described above
- a miRNA precursor e.g., pre-miRNA or pri-miRNA
- the term “probe” includes a polynucleotide that is used for specifically detecting an RNA resulting from the expression of a gene or a polynucleotide derived from the RNA, and/or a polynucleotide complementary thereto.
- primer includes a polynucleotide that specifically recognizes and amplifies an RNA resulting from the expression of a gene or a polynucleotide derived from the RNA, and/or a polynucleotide complementary thereto.
- the complementary polynucleotide means a polynucleotide in a complementary base relationship based on A:T (U) and G:C base pairs with the full-length sequence of a polynucleotide consisting of a nucleotide sequence defined by any of SEQ ID NOs: 1 to 100 or a nucleotide sequence derived from the nucleotide sequence by the replacement of the nucleotide "U” (or “u") with the nucleotide "T” (or "t”), or a partial sequence thereof (here, this full-length or partial sequence is referred to as a plus strand for the sake of convenience).
- a complementary strand is not limited to a sequence completely complementary to the nucleotide sequence of the target plus strand and may have a complementary relationship to an extent that permits hybridization under stringent conditions to the target plus strand.
- stringent conditions refers to conditions under which a nucleic acid probe hybridizes to its target sequence to a larger extent (e.g., a measurement value equal to or larger than a mean of background measurement values + a standard deviation of the background measurement values> ⁇ 2) than that for other sequences.
- the stringent conditions are dependent on a sequence and differ depending on an environment where hybridization is performed.
- a target sequence complementary 100% to the nucleic acid probe can be identified by controlling the stringency of hybridization and/or washing conditions. Specific examples of the “stringent conditions” will be mentioned later.
- the term “variant” means, in the case of a nucleic acid, a natural variant attributed to polymorphism, mutation, or the like; a variant containing the deletion, substitution, addition, or insertion of 1, 2, or 3 or more nucleotides in a nucleotide sequence represented by any of SEQ ID NOs: 1 to 100 or a nucleotide sequence derived from the nucleotide sequence by the replacement of the nucleotide "U” (or “u") with the nucleotide "T” (or “t"), or a partial sequence thereof; a variant containing the deletion, substitution, addition, or insertion of 1 or 2 or more nucleotides in a nucleotide sequence of a premature miRNA of a sequence represented by any of SEQ ID NOs: 1 to 100 or a nucleotide sequence derived from the nucleotide sequence by the replacement of the nucleotide "U” (or “u”) with the nucleo
- a variant can be prepared by use of a well-known technique such as site-directed mutagenesis or PCR-based mutagenesis.
- the term “percent(%) identity” can be determined with or without an introduced gap, using a protein or gene search system based on BLAST or FASTA described above (Zhang et al., 2000; Altschul et al. 1990; Pearson et al. 1988).
- derivative is meant to include a modified nucleic acid, for example, a derivative labeled with a fluorophore or the like, a derivative containing a modified nucleotide (e.g., a nucleotide containing a group such as halogen, alkyl such as methyl, alkoxy such as methoxy, thio, or carboxymethyl, and a nucleotide that has undergone base rearrangement, double bond saturation, deamination, replacement of an oxygen molecule with a sulfur atom, etc.), PNA (peptide nucleic acid; Nielsen et al. 1991), and LNA (locked nucleic acid; Obika et al. 1998) without any limitation.
- a modified nucleotide e.g., a nucleotide containing a group such as halogen, alkyl such as methyl, alkoxy such as methoxy, thio, or carboxymethyl
- PNA peptide nucleic acid
- LNA locked
- the “nucleic acid” capable of specifically binding to a polynucleotide selected from the miRNAs described above is a synthesized or prepared nucleic acid and specifically includes a “nucleic acid probe” or a “primer”.
- the “nucleic acid” is utilized directly or indirectly for detecting the presence or absence of cancer in a subject, for diagnosing the severity, the degree of amelioration, or the therapeutic sensitivity of cancer, or for screening for a candidate substance useful in the prevention, amelioration, or treatment of cancer.
- nucleic acid includes a nucleotide, an oligonucleotide, and a polynucleotide capable of specifically recognizing and binding to a transcript represented by any of SEQ ID NOs: 1 to 100, or a synthetic cDNA nucleic acid thereof in vivo, particularly, in a sample such as a body fluid (e.g., blood or urine), in relation to the development of cancer.
- a body fluid e.g., blood or urine
- the nucleotide, the oligonucleotide, and the polynucleotide can be effectively used as probes for detecting the aforementioned gene expressed in vivo, in tissues, in cells, or the like on the basis of the properties described above, or as primers for amplifying the aforementioned gene expressed in vivo.
- E-value As used within the scope of the disclosure, each of the terms “E-value”, “accuracy”, “AUC”, “sensitivity”, and “specificity” is generally to be understood to have the common definition that is well appreciated by people skilled in the art, and is specifically defined as follows: [0084]
- P-value or “P”, is considered to be exchangeable with "/>-value” or "p” , and refers to a probability at which a more extreme statistic than that actually calculated from data under a null hypothesis is observed in a statistical test. Thus, smaller “P” or “P value” means more significant difference between subjects to be compared.
- AUC means area under the curve of a Receiver Operating Characteristic curve.
- accuracy means a value of (the number of true positives + the number of true negatives)/(the total number of cases). The accuracy indicates the ratio of samples that were correctly identified to all samples and serves as a primary index to evaluate detection performance.
- sensitivity means a value of (the number of true positives)/(the number of true positives + the number of false negatives). High sensitivity allows cancer to be detected, leading to clinical treatment interventions.
- the term “specificity” means a value of (the number of true negatives)/ (the number of true negatives + the number of false positives). High specificity prevents needless extra examination for healthy subjects misjudged as being cancer patients, leading to reduction in burden on patients and reduction in medical expense.
- determination of the expression profile of the miRNA biomarker set substantially includes the determination of the expression level of each and every miRNA contained in the miRNA biomarker set.
- expression levels for all of the miRNA contained in the miRNA biomarker set can be determined simultaneously in one single experiment that is well-controlled. Yet optionally, it is possible that expression levels of these miRNAs are determined in more than one experiment and by different experiment procedure.
- measuring or detecting the expression of any of the miRNAs contained in the miRNA biomarker set comprises measuring or detecting any nucleic acid transcript corresponding to the miRNA.
- expression can be detected or measured on the basis of miRNA or corresponding reverse transcribed cDNA levels.
- Any quantitative or qualitative method for measuring RNA levels, or cDNA levels can be used. Suitable methods of detecting or measuring miRNA or cDNA levels include, for example, Northern Blotting, microarray analysis, RNA- sequencing, RNA in-situ hybridization, or a nucleic acid amplification procedure, such as reverse- transcription PCR (RT-PCR) or real-time RT-PCR, also known as quantitative RT-PCR (qRT-PCR), or digital RT-PCR. Such methods are well known in the art (see e.g., Green and Sambrook et al. 2012). Other techniques include digital, multiplexed analysis of gene expression, such as the nCounter® (NanoString Technologies, Seattle, WA) gene expression assays, which are further described in US20100112710 and US20100047924.
- Detecting a nucleic acid of interest generally involves hybridization between a target (e.g. miRNA or cDNA) and a probe. Sequences of the miRNAs used in various cancer gene expression profiles are known. Therefore, one of skills in the art can readily design hybridization probes for detecting those miRNAs (see e.g., Green and Sambrook et al. 2012). For example, polynucleotide probes that specifically bind to the miRNA transcripts described herein (or cDNA synthesized therefrom) can be created using the nucleic acid sequences of the miRNA or cDNA targets themselves by routine techniques (e.g., PCR or synthesis).
- the term “probe” means a part or portion of a polynucleotide sequence comprising about 10 or more contiguous nucleotides, about 15 or more contiguous nucleotides, about 20 or more contiguous nucleotides.
- the polynucleotide probes will comprise 10 or more nucleic acids, 15 or more nucleic acids, or 20 or more nucleic acids.
- the probe may have a sequence identity to a complement of the target sequence of about 90% or more, such as about 95% or more (e.g., about 98% or more or about 99% or more) as determined, for example, using the well-known Basic Local Alignment Search Tool (BLAST) algorithm (available through the National Center for Biotechnology Information (NCBI), Bethesda, Md.).
- BLAST Basic Local Alignment Search Tool
- Each probe may be substantially specific for its target, to avoid any cross hybridization and false positives.
- An alternative to using specific probes is to use specific reagents when deriving materials from transcripts (e.g., during cDNA production, or using target-specific primers during amplification). In both cases specificity can be achieved by hybridization to portions of the targets that are substantially unique within the group of miRNAs being analyzed, for example hybridization to the poly A tail would not provide specificity. If a target has multiple splice variants, it is possible to design a hybridization reagent that recognizes a region common to each variant and/or to use more than one reagent, each of which may recognize one or more variants.
- Stringency of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes may require higher temperatures for proper annealing, while shorter probes may require lower temperatures.
- Hybridization generally depends on the ability of denatured nucleic acid sequences to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature that can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so.
- “Stringent conditions” or “high stringency conditions,” as defined herein, are identified by, but not limited to, those that: (1) use low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) use during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at42°C; or (3) use 50% formamide, 5> ⁇ SSC (0.75 MNaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5x Denhardfs solution, sonicated salmon sperm DNA(50pg/ml), 0.1% SDS, and
- Modely stringent conditions are described by, but not limited to, those in Sambrook et al. 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and % SDS) less stringent than those described above.
- An example of moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20% formamide, 5xSSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardfs solution, 10% dextran sulfate, and 20 mg/mL denatured sheared salmon sperm DNA, followed by washing the filters in 1 xSSC at about 37-50°C.
- 5xSSC 150 mM NaCl, 15 mM trisodium citrate
- 50 mM sodium phosphate pH 7.6
- 5x Denhardfs solution 10% dextran sulfate
- measuring the expression of the foregoing miRNAs in a biological sample can comprise, for instance, contacting a sample containing or suspected of containing cancer cells with polynucleotide probes specific to the miRNAs of interest, or with primers designed to amplify a portion of the miRNAs of interest, and detecting binding of the probes to the nucleic acid targets or amplification of the nucleic acids, respectively.
- PCR primers are known in the art (see e.g., Green and Sambrook et al. 2012).
- miRNAs obtained from a sample may be subjected to qRT-PCR. Reverse transcription may occur by any methods known in the art, such as through the use of an Omniscript RT Kit (Qiagen). The resultant cDNA may then be amplified by any amplification technique known in the art. miRNA expression may then be analyzed through the use of, for example, control samples as described below. As described herein, the over- or under-expression of miRNAs relative to controls may be measured to determine a miRNA expression profile for an individual biological sample. Similarly, detailed protocols for preparing and using microarrays to analyze miRNA expression are known in the art and described herein.
- RNA-sequencing also called Whole Transcriptome Shotgun Sequencing
- RNA-seq also called Whole Transcriptome Shotgun Sequencing
- RNA-seq refers to any of a variety of high-throughput sequencing techniques used to detect the presence and quantity of RNA transcripts in real time. See Wang, Z., M. Gerstein, and M. Snyder, RNA-Seq: a revolutionary tool for transcriptomics, NAT REV GENET, 2009. 10(1): p. 57-63.
- RNA-seq can be used to reveal a snapshot of a sample’s miRNAs from a genome at a given moment in time.
- miRNA is converted to cDNA fragments via reverse transcription prior to sequencing, and, in certain embodiments, miRNA can be directly sequenced without conversion to cDNA.
- Adaptors may be attached to the 5’ and/or 3’ ends of the miRNAs, and the miRNA or cDNA may optionally be amplified, for example by PCR.
- the fragments are then sequenced using high-throughput sequencing technology, such as, for example, those available from Roche (e.g., the 454 platform), Illumina, Inc., and Applied Biosystem (e.g., the SOLiD system).
- FIGS. 1A-1C show a case flow diagram for lung cancer dataset (FIG. 1A, split into a discovery and a validation set) and for ovarian, liver and bladder cancer datasets (FIG. IB, combined into a single validation dataset after removing redundant samples), and summarize the patient and tumor characteristics of patients with lung, bladder, ovarian, and liver cancers and demographic information of the corresponding controls (FIG. 1C);
- FIGS. 2A-2G show the development and validation of the 4-miRNA diagnostic model in the lung cancer data set, with FIG. 2A showing determination of the optimal number (dotted line) of miRNAs for the diagnostic model by 10-fold cross validation in the discovery set; FIG. 2B showing ROC analysis in the discovery set; FIG. 2C showing distribution of normalized diagnostic index in the discovery set; FIG. 2D showing ROC analysis in the validation set; FIG. 2E showing distribution of normalized diagnostic index in the validation set; FIG. 2F showing comparison of normalized diagnostic index of paired serum samples (pre- vs. post-surgery) of 180 lung cancer patients; and FIG. 2G showing distribution of normalized diagnostic index in the clinical subsets of the validation set. Dotted horizontal lines represent the cut-point for the normalized diagnostic index of our model. The percentages shown in the graph were sensitivities in each cancer subgroup.
- FIGS. 3 A and 3B show the performance of 4-miRNA diagnostic model in the datasets of additional cancers, with FIG. 3 A showing ROC analysis, and FIG. 3B showing distribution of normalized diagnostic index the 4-miRNA model.
- the percentages shown in the graph were sensitivities of each cancer type and specificity of non-cancer controls;
- FIGS. 4A and 4B show the ROC analysis and distribution of normalized diagnostic index across age and gender groups in the lung cancer dataset.
- the present disclosure provides an approach, comprising a method, a kit and a computerized system, that is capable of accurately and reliably detecting one or multiple human cancers for a subject based on the expression profile of an miRNA biomarker set consisting of at least one miRNA that is determined from a biological sample obtained from the subject.
- a detection method capable of achieving diagnostic accuracy having an AUC value greater than approximately 0.780 which substantially includes the following three steps:
- Step (1) determining the expression profile of the miRNA biomarker set
- Step (2) calculating a diagnostic index of the biological sample based on the expression profile of the miRNA biomarker set.
- Step (3) classifying the subject as having the cancer or not based on the value of the calculated diagnostic index. If the calculated diagnostic index is greater than or equal to a pre determined threshold, the subject is classified as having the cancer; or if otherwise the subject is classified as not having the cancer.
- the miRNA biomarker set includes hsa-miR-5100, and optionally can further include any one or a combination of the miRNAs listed in Table 1 (see EXAMPLE 1).
- the miRNA biomarker set may further include miRNA(s) from the top 2-100 miRNAs, or alternatively may further include miRNA(s) from the top 2-50 miRNAs, or alternatively may further include miRNA(s) from the top 2-20 miRNAs, or alternatively may further include miRNA(s) from the top 2-4 miRNAs, in Table 1.
- the miRNA biomarker set consists of the top 4 miRNAs (i.e.
- hsa-miR-5100, hsa-miR-1343-3p, hsa-miR-1290, and hsa-miR-4787-3p there can be different AUC cut-off levels (e.g. 0.780, 0.850, 0.950, 0.990, and 0.999), or different sensitivity-specificity levels (e.g. 68%-99%, 68%-99%, 83%-99%, and 99%-99%), at least at which the method is capable of accurately detecting certain cancer types.
- the method can accurately detect lung cancer and gastric cancer at the AUC > 0.999, and/or at a sensitivity > 99.0% and having a specificity > 99.0%.
- the diagnostic index can be calculated based on formula (I).
- the calculation can be based on an unweighted model or on a weighted model.
- different models e.g. limma model, logistic regression model, etc.
- the diagnostic index is calculated via a weighted model using weights from the limma model.
- the pre-determined threshold can be set as 1110 to thereby allow the method to have a specificity >0.95; or optionally, the pre-determined threshold can be set as 1200 to thereby allow the method to have a specificity >0.99.
- the diagnostic index calculated in step (2) can further undergo a normalization process, and the step (3) can determine the cancer classification based on whether the normalized diagnostic index is no less than or greater than a preset cut-point.
- the normalization process can be based on formula: where the parami OCation and param SCaie are respectively a location parameter and a scale parameter configured to allow the normalized diagnostic index to be within a range no less than a first preset value and no greater than a second preset value.
- the parami OCation and param SCaie can be selected as 600 and 1000 respectively to thereby allow the normalized diagnostic index to be between 0 and 10, and under such normalization, the preset cut-point can be set as 5.1 to give a specificity > 0.95 or as 6.0 to give a specificity > 0.99.
- the biological sample can advantageously be a liquid biopsy sample such as a blood sample, a serum sample, a plasma sample, a urine sample, a saliva sample, or a spatum sample, etc.
- Determination of the expression profile of the miRNA biomarker set can be realized by means of a variety of probe-based approaches including Northern Blotting, microarray analysis, RNA-sequencing, or RNA in-situ hybridization, or by means of a variety of amplification-dependent approaches including reverse-transcription PCR (RT-PCR), quantitative RT-PCR (qRT-PCR), or digital RT-PCR.
- RT-PCR reverse-transcription PCR
- qRT-PCR quantitative RT-PCR
- digital RT-PCR digital RT-PCR
- the method may further comprise a step of performing an evaluation of the subject, so as to determine if the subject is diagnosed as having the cancer (if the subject is absent of cancer before) or if the subject has recurrence of the cancer (if the subject has been treated to remove, or be free of, the cancer before).
- the evaluation may further include physical examination, pathological examination of a biopsy from the subject, immunohistochemistry examination, or imaging examination including x-rays, computed tomography (CT), ultrasonography, magnetic resonance imaging, etc.
- the method may further comprise a step of administering to the subject a therapeutic regimen, such as surgery, radiotherapy, chemotherapy, hormonal therapy, targeted therapy, immunotherapy or the combination thereof, when the subject is classified as having the cancer.
- a therapeutic regimen such as surgery, radiotherapy, chemotherapy, hormonal therapy, targeted therapy, immunotherapy or the combination thereof, when the subject is classified as having the cancer.
- kit that can be employed to specifically implement the various steps of the method according to the different embodiments as described above in the first aspect of this section is further provided.
- the kit substantially include certain articles (i.e. component (1), including one or more nucleic acids that can specifically recognize each miRNA in the miRNA biomarker set, and optionally one or more amplification primers) that can be used to determine the expression profile of the miRNA biomarker set and certain instructions (i.e. component (2)) for calculating the diagnostic index and for cancer classification.
- component (1) including one or more nucleic acids that can specifically recognize each miRNA in the miRNA biomarker set, and optionally one or more amplification primers
- certain instructions i.e. component (2)
- each of the nucleic acids in component (1) may comprise a polynucleotide capable of specifically hybridizing under a stringent condition to (a) a polynucleotide comprising or consisting of a nucleotide sequence as set forth in SEQ ID NOS: 1-100, 1-50, 1-20 or 1-4, a derivative thereof, a variant thereof having at least 80% sequence identity, or a fragment thereof comprising 15 or more consecutive nucleotides; or (b) a polynucleotide comprising or consisting of a nucleotide sequence complementary to a nucleotide sequence of SEQ ID NOS: 1-100, 1-50, 1-20 or 1-4, a derivative thereof, a variant thereof having at least 80% sequence identity, or a fragment thereof comprising 15 or more consecutive nucleotides.
- kits regarding to the following elements/features, including: what miRNA components are included in the miRNA biomarker set; whether and how a normalization is performed over the diagnostic index; how the subject is classified as having the cancer or not, what samples can be used for the biological sample, and what detection accuracy level is to be achieved, etc.
- the specific details for these different embodiments can be referenced to the various embodiments of the method as described above, and will be skipped herein for conciseness.
- a computerized solution is further provided, which substantially serves, in a computerized and automatic manner, to implement the various steps of the method as described above in the first aspect of this section.
- Such a computerized solution may be applied in a situation where the implementation of the various steps (l)-(3) of the method described above is to be automated by running a software program comprising program instructions in a computer, which brings about advantages such as high efficiency and great convenience.
- such a computerized solution may include a computerized system or computer system, which comprises a processor (i.e. controller) and a computer-readable non- transitory storage medium that is communicatively coupled to the processor.
- the computer- readable non-transitory storage medium is configured to store program instructions that are executable by the processor, thereby causing the processor to execute the various different steps in the method as described above, including:
- Step (1) determining the expression profile of the miRNA biomarker set
- Step (2) calculating a diagnostic index of the biological sample based on the expression profile of the miRNA biomarker set and according to formula (I); and [0126] Step (3): classifying the subject as having the cancer or not based on the value of the calculated diagnostic index.
- processor is interpreted to be exchangeable with “central controller” or “central computing unit (CPU)”, and can be deemed to be a single core or multi core processor, or a plurality of processors for parallel processing.
- non-transitory is intended to describe a tangible computer-readable storage medium excluding propagating electromagnetic signals, but are not intended to otherwise limit the type of physical computer-readable storage device that is encompassed by the phrase. Examples may include any tangible or non-transitory storage media or memory media such as electronic, magnetic, or optical media (e.g., disk or CD/DVD-ROM), or non-volatile memory storage (e.g., “flash” memory), etc.
- the system 100 can, in addition to the processor 10 and the computer-readable non-transitory storage medium 20, further comprise a bus 30, a memory 40, an I/O interface 50, and a communication interface 60.
- the processor 10, the storage medium 20, the memory 40, the I/O interface 50 and the communication interface 60 are all communicatively coupled with one another through the bus 30.
- the storage medium 20 stores computer-executable program instructions which, when executed by the processor 10, cause the processor 10 to execute steps (l)-(3) of the method as described above.
- the memory 40 is configured to transiently store the program instructions obtained from the storage medium 20, and the processor 10 is configured to execute the program instructions transiently stored in the memory 40.
- the I/O interface 50 allows an input/output between the system 100 and a user, realizing the control of the system 100.
- the communication interface 60 can allow the system 100 to be communicatively connected to another computing device to exchange data. It is to be noted that these computer hardware components can be locally arranged, or can be remotely arranged via a network, such as an intranet, an internet, or a cloud.
- the original lung cancer study established a 2-miRNA diagnostic model (referred to as the “original 2-miRNA model” in this study) with high sensitivity and specificity for the detection of lung cancer (Asakura et al. 2020).
- the objective of the current study was initially set to use this dataset to develop and validate a new diagnostic model that may out-perform the original 2-miRNA model for lung cancer detection. As datasets for additional cancer types were identified, the new model was evaluated for performance to detect other cancers.
- Serum sample collection has been previously described in the original publications (Asakura et al. 2020; Yokoi et al. 2018; Usuba et al. 2019, Yamamoto et al. 2020). Briefly, serum samples were collected from cancer patients who were referred or admitted to the National Cancer Center Hospital (NCCH) between 2008 to 2016 prior to surgical operation, and stored at 4 °C for one week before being stored at -20 °C until further use. Cancer patients who were treated with preoperative chemotherapy and radiotherapy prior to serum collection were excluded.
- NCCH National Cancer Center Hospital
- NCCH National Center for Geriatrics and Gerontology
- YMC Yokohama Minoru Clinic
- 3DGene ® miRNA Labeling kit labeled by 3DGene ® miRNA Labeling kit and hybridized to 3D- Gene ® Human miRNA Oligo Chip (Toray Industries, Kanagawa, Japan) designed to investigate 2588 miRNA sequences registered in miRBase release 21.
- 3D- Gene ® Human miRNA Oligo Chip Toray Industries, Kanagawa, Japan
- RNA was determined when signal intensity was greater than mean plus two times standard deviation of the negative control signals, and in using the negative control signals the top and bottom 5% of the ranked signal intensities were removed. Background subtraction was performed by subtracting the mean signal of negative control signals (after removing top and bottom 5% as ranked by signal intensities) from the miRNA signal. Normalization across microarrays was achieved by calibrating according to three pre-selected internal control miRNAs (miR-149-3p, miR-2861, and miR-4463). [0141] 2.4. Diagnostic Model Development
- Linear Model for Microarray Data (limma) (Ritchie et al. 2015) was performed in the discovery set to evaluate the statistical significance of differential miRNA expression between lung cancer vs. non-cancer.
- a diagnostic index was calculated as a linear sum of miRNA expression levels weighted by limma statistics. The cut-point for the diagnostic index was chosen to ensure no misclassification of non-cancer controls in the discovery set to minimize false positives as the diagnostic model may potentially be used as a screening test in the at-risk general public.
- the diagnostic performance for identifying cancer vs. non-cancer was determined by AUC of the ROC curve analysis, sensitivity, and specificity. Comparing AUC of two ROC curves was done with roc.test function with bootstrapping method from pROC package. Comparing paired sensitivities for the lung cancer clinical subsets of paired pre- vs. post-surgical samples was performed by McNemar test limma analysis was carried out using Bioconductor package limma (The Bioconductor Open Source Software For Bioinformatics (accessed on August 27, 2020). All statistical analysis was performed using R version 4.0.5 (The R Project for Statistical Computing (accessed on July 15, 2020)).
- the lung cancer dataset included 1566 lung cancer patients and 2178 non-cancer controls (FIG. 1A) (Asakura et al. 2020).
- the ovarian cancer dataset consisted of 333 ovarian cancer patients and 2759 non-cancer controls, as well as patients with breast, colorectal, esophageal, gastric, liver, lung, pancreatic, and sarcoma cancers (FIG. IB) (Yokoi et al. 2018).
- liver and bladder cancer datasets included 345 liver cancer/1033 non-cancer and 392 bladder cancer/100 non-cancer participants, respectively, in addition to patients with biliary tract, breast, colorectal, esophageal, gastric, glioma, lung, ovarian, pancreatic, prostate, and sarcoma cancers (FIG. IB) (Usuba et al. 2019, Yamamoto et al. 2020). With the lung cancer dataset left intact, redundant samples within the other three datasets that showed correlations either among themselves or with samples in the lung cancer dataset being greater than 0.99 were removed.
- the discovery set included 208 lung cancer patients and 208 non-cancer controls, matched by age, sex, and smoking status (Asakura et al. 2020).
- the validation set included 1358 lung cancer patients and 1970 non-cancer controls.
- the patients with lung cancer included 57% male, 62% former or current smokers, 78% adenocarcinoma, 14% squamous carcinoma, 72% stage I, 15% stage II, and 13% stage III (FIG. 1C).
- the 392 bladder cancer patients were of mean age 68 y, 72% male, 5% metastatic, 12% nodal positive, 77% T2 or below, and 80% high grade (FIG. 1C).
- the 333 ovarian cancer patients were of mean age 57 y, 25% stage I, 10% stage II, 55% serous, 19% clear cell, and 13% endometrioid histology (FIG. 1C).
- the 348 liver cancer patients were of mean age 68 y, 78% male, 37% stage I, and 33% stage II (FIG. 1C). No detailed demographic information and tumor characteristics for the other cancers were provided by the original studies.
- Table 1 cancer discovery set.
- the cut-point of six was chosen to ensure no misclassification of the non-cancer controls in the discovery set to minimize the false positives, which resulted in 98% sensitivity and 100% specificity (FIG. 2C), compared to 99% for both sensitivity and specificity for the original 2- miRNA model (Asakura et al. 2020).
- the new model also resulted in 99% for both sensitivity and specificity (FIG. 2E), whereas the original 2-miRNA model showed 95% sensitivity and 99% specificity (Asakura et al. 2020).
- the performance of the 4-miRNA model was assessed in clinical subsets of the validation set, as defined by clinical stage, T stage, N stage, M stage, and Histology. Across all clinical subsets, the 4-miRNA model showed sensitivities of approximately 99% or above (FIG. 2G, Table 2), which were superior to the sensitivities of the original 2-miRNA model (Table 2). In particular for early stage lung cancer, e.g., for both patients with stage I lung cancer and patients with T1 tumors, the 4-miRNA model demonstrated >99% sensitivity (FIG. 2G, Table 2), compared to the sensitivities of 95.4 and 95.9%, respectively, for the 2-miRNA model (Table 2).
- the 4-miRNA model In the prevalent histological types of adenocarcinoma and squamous cell carcinoma, the 4-miRNA model also demonstrated superior performance (FIG. 2G, Table 2), compared to the original 2-miRNA model (Table 2). Table 2. Comparison of sensitivities in the clinical subsets of the lung cancer validation set between the original 2-miRNA model and the new 4-miRNA model, while maintaining a specificity of >99%. [0156] Data on paired serum samples (pre- vs. post-surgery) were also available for 180 patients. The diagnostic indices of the 4-miRNA model for post-surgery serum samples were reduced to normal levels below the diagnostic index cut-point (FIG. 2F).
- the performance of the 4-miRNA model was further assessed in the combined dataset of 3792 patients, including 2038 cancer patients across 12 different cancer types and 1754 non cancer controls.
- the bladder, liver, and ovarian cancers had the largest sample sizes with >300 patients in each.
- the 4- miRNA model showed very strong performances with AUCs >0.95 in biliary tract, bladder, colorectal, esophageal, gastric, glioma, liver, ovarian, pancreatic, and prostate cancers, and an AUC of 0.876 in Sarcoma (FIG. 3A).
- the 4-miRNA model demonstrated high sensitivities in the range from 83.2 to 100% for biliary tract, bladder, colorectal, esophageal, gastric, glioma, liver, pancreatic, and prostate cancers, and reasonable sensitivities of 68.2 and 72.0% for ovarian cancer and sarcoma, respectively (FIG. 3B).
- the 4-miRNA model maintained a high specificity of 99.3%.
- the 4-miRNA model can detect 12 cancer types (biliary tract, bladder, colorectal, esophageal, gastric, glioma, live, lung, ovarian, pancreatic, prostate, and sarcoma) simultaneously with high sensitivities (80-100% for ten cancer types, and -70% for two cancer types) while still maintaining a very high specificity of 99% that is typically required for a screening test to be useful in at-risk general population.
- cancer types biliary tract, bladder, colorectal, esophageal, gastric, glioma, live, lung, ovarian, pancreatic, prostate, and sarcoma
- Galleri and PanSeer are developed as methylation- based epigenetic signatures (Klein et al. 2021; Chen 2020).
- CCGA Circulating Cell-free Genome Atlas
- PanSeer assay which targeted only 477 methylated genomic regions retrospectively analyzed plasma samples from a group of asymptomatic individuals enrolled in a longitudinal cancer monitoring study, and demonstrated a high sensitivity of 95% in 98 individuals who later were diagnosed with one of five cancers (stomach, esophageal, colorectal, lung, and liver cancer) within four years of blood draw (pre diagnosis samples), but with a lower specificity of 96% in 207 healthy controls (Chen et al. 2020).
- what was puzzling with PanSeer was that when it was evaluated in 113 post-diagnosis plasma samples, the test only showed a lower 88% sensitivity (Chen et al. 2020) .
- the current MCED tests in development generally showed sensitivities in the range of 60-70% when a high specificity of 99% was mandated.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163208506P | 2021-06-09 | 2021-06-09 | |
PCT/US2022/032423 WO2022261039A2 (en) | 2021-06-09 | 2022-06-07 | Cancer detection method, kit, and system |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4352266A2 true EP4352266A2 (de) | 2024-04-17 |
Family
ID=84426392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP22820856.7A Pending EP4352266A2 (de) | 2021-06-09 | 2022-06-07 | Krebsdetektionsverfahren, kit und system |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4352266A2 (de) |
JP (1) | JP2024523848A (de) |
CN (1) | CN117500941A (de) |
AU (1) | AU2022289858A1 (de) |
CA (1) | CA3221494A1 (de) |
WO (1) | WO2022261039A2 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3647422B1 (de) * | 2017-06-29 | 2024-07-24 | Toray Industries, Inc. | Kit, vorrichtung und verfahren zur detektion von lungenkrebs |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9495515B1 (en) * | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
US20120041274A1 (en) * | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
WO2013107459A2 (en) * | 2012-01-16 | 2013-07-25 | Herlev Hospital | Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples |
US9708667B2 (en) * | 2014-05-13 | 2017-07-18 | Rosetta Genomics, Ltd. | MiRNA expression signature in the classification of thyroid tumors |
US20170283883A1 (en) * | 2014-09-09 | 2017-10-05 | Fondazione Istituto Firc Di Oncologia Molecolare | Methods for lung cancer detection |
WO2018199275A1 (ja) * | 2017-04-28 | 2018-11-01 | 東レ株式会社 | 卵巣腫瘍の検出のためのキット、デバイス及び方法 |
-
2022
- 2022-06-07 JP JP2023576034A patent/JP2024523848A/ja active Pending
- 2022-06-07 AU AU2022289858A patent/AU2022289858A1/en active Pending
- 2022-06-07 WO PCT/US2022/032423 patent/WO2022261039A2/en active Application Filing
- 2022-06-07 CN CN202280041034.8A patent/CN117500941A/zh active Pending
- 2022-06-07 CA CA3221494A patent/CA3221494A1/en active Pending
- 2022-06-07 EP EP22820856.7A patent/EP4352266A2/de active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2022261039A2 (en) | 2022-12-15 |
WO2022261039A3 (en) | 2023-01-19 |
JP2024523848A (ja) | 2024-07-02 |
CA3221494A1 (en) | 2022-12-15 |
CN117500941A (zh) | 2024-02-02 |
AU2022289858A1 (en) | 2024-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5843840B2 (ja) | 新しい癌マーカー | |
ES2656487T3 (es) | Evaluación de la respuesta a la terapia de neoplasmas neuroendocrinos gastroenteropancreáticas (GEP-NEN) | |
JP6408380B2 (ja) | 癌を患うリスクのある被検体を診断するための方法およびキット | |
JP2014509189A (ja) | 結腸ガン遺伝子発現シグネチャーおよび使用方法 | |
US11827938B2 (en) | Methods of prostate cancer prognosis | |
US10287634B2 (en) | RNA-biomarkers for diagnosing prostate cancer | |
WO2015073949A1 (en) | Method of subtyping high-grade bladder cancer and uses thereof | |
EP3122905B1 (de) | Zirkulierende mikro-rnas als biomarker für endometriose | |
US20240093312A1 (en) | Detection method | |
JP6611411B2 (ja) | 膵臓がんの検出キット及び検出方法 | |
EP3548631B1 (de) | Risikobewertungen auf basis der expression der variante 7 von humaner phosphodiesterase 4d | |
WO2022261039A2 (en) | Cancer detection method, kit, and system | |
US20210079479A1 (en) | Compostions and methods for diagnosing lung cancers using gene expression profiles | |
JP2024519082A (ja) | 肝細胞がんのdnaメチル化バイオマーカー | |
US20240209451A1 (en) | Cancer detection method, kit, and system | |
WO2019245587A1 (en) | Methods and compositions for the analysis of cancer biomarkers | |
US11427874B1 (en) | Methods and systems for detection of prostate cancer by DNA methylation analysis | |
WO2024192053A1 (en) | Methods of developing cancer diagnostic models and uses thereof in developing cancer detection methods | |
CN111315897A (zh) | 用于黑素瘤检测的方法 | |
Bender et al. | LASSO logistic regression reveals a mixed MiRNA and serum-marker classifier for prediction of immunotherapy response in liquid biopsies of melanoma patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20240108 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |